257 related articles for article (PubMed ID: 16682621)
1. Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor.
Xin L; Teitell MA; Lawson DA; Kwon A; Mellinghoff IK; Witte ON
Proc Natl Acad Sci U S A; 2006 May; 103(20):7789-94. PubMed ID: 16682621
[TBL] [Abstract][Full Text] [Related]
2. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines.
Wang Y; Romigh T; He X; Orloff MS; Silverman RH; Heston WD; Eng C
Hum Mol Genet; 2010 Nov; 19(22):4319-29. PubMed ID: 20729295
[TBL] [Abstract][Full Text] [Related]
3. Crosstalking between androgen and PI3K/AKT signaling pathways in prostate cancer cells.
Lee SH; Johnson D; Luong R; Sun Z
J Biol Chem; 2015 Jan; 290(5):2759-68. PubMed ID: 25527506
[TBL] [Abstract][Full Text] [Related]
4. Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in Prostate Cancer.
Yan Y; Huang H
Adv Exp Med Biol; 2019; 1210():319-331. PubMed ID: 31900915
[TBL] [Abstract][Full Text] [Related]
5. Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer.
Gao H; Ouyang X; Banach-Petrosky WA; Gerald WL; Shen MM; Abate-Shen C
Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14477-82. PubMed ID: 16973750
[TBL] [Abstract][Full Text] [Related]
6. The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way.
Mediwala SN; Sun H; Szafran AT; Hartig SM; Sonpavde G; Hayes TG; Thiagarajan P; Mancini MA; Marcelli M
Prostate; 2013 Feb; 73(3):267-77. PubMed ID: 22821817
[TBL] [Abstract][Full Text] [Related]
7. Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer.
Mirkheshti N; Park S; Jiang S; Cropper J; Werner SL; Song CS; Chatterjee B
Oncotarget; 2016 Sep; 7(38):62240-62254. PubMed ID: 27557496
[TBL] [Abstract][Full Text] [Related]
8. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer.
Sircar K; Yoshimoto M; Monzon FA; Koumakpayi IH; Katz RL; Khanna A; Alvarez K; Chen G; Darnel AD; Aprikian AG; Saad F; Bismar TA; Squire JA
J Pathol; 2009 Aug; 218(4):505-13. PubMed ID: 19402094
[TBL] [Abstract][Full Text] [Related]
9. Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer.
Dulinska-Litewka J; McCubrey JA; Laidler P
Curr Med Chem; 2013; 20(1):144-57. PubMed ID: 23033951
[TBL] [Abstract][Full Text] [Related]
10. In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis.
Chesire DR; Ewing CM; Gage WR; Isaacs WB
Oncogene; 2002 Apr; 21(17):2679-94. PubMed ID: 11965541
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in
Yan Y; An J; Yang Y; Wu D; Bai Y; Cao W; Ma L; Chen J; Yu Z; He Y; Jin X; Pan Y; Ma T; Wang S; Hou X; Weroha SJ; Karnes RJ; Zhang J; Westendorf JJ; Wang L; Chen Y; Xu W; Zhu R; Wang D; Huang H
EMBO Mol Med; 2018 Apr; 10(4):. PubMed ID: 29523594
[TBL] [Abstract][Full Text] [Related]
12. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
Pungsrinont T; Kallenbach J; Baniahmad A
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681745
[TBL] [Abstract][Full Text] [Related]
13. Sin1 promotes proliferation and invasion of prostate cancer cells by modulating mTORC2-AKT and AR signaling cascades.
Huang Y; Feng G; Cai J; Peng Q; Yang Z; Yan C; Yang L; Wang Z
Life Sci; 2020 May; 248():117449. PubMed ID: 32088212
[TBL] [Abstract][Full Text] [Related]
14. Id4 deficiency attenuates prostate development and promotes PIN-like lesions by regulating androgen receptor activity and expression of NKX3.1 and PTEN.
Sharma P; Knowell AE; Chinaranagari S; Komaragiri S; Nagappan P; Patel D; Havrda MC; Chaudhary J
Mol Cancer; 2013 Jun; 12():67. PubMed ID: 23786676
[TBL] [Abstract][Full Text] [Related]
15. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor.
Fan W; Yanase T; Morinaga H; Okabe T; Nomura M; Daitoku H; Fukamizu A; Kato S; Takayanagi R; Nawata H
J Biol Chem; 2007 Mar; 282(10):7329-38. PubMed ID: 17202144
[TBL] [Abstract][Full Text] [Related]
17. Cytosolic phospholipase A2α sustains pAKT, pERK and AR levels in PTEN-null/mutated prostate cancer cells.
Hua S; Yao M; Vignarajan S; Witting P; Hejazi L; Gong Z; Teng Y; Niknami M; Assinder S; Richardson D; Dong Q
Biochim Biophys Acta; 2013 Jun; 1831(6):1146-57. PubMed ID: 23500889
[TBL] [Abstract][Full Text] [Related]
18. Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways.
Hu Y; Sun H; Owens RT; Wu J; Chen YQ; Berquin IM; Perry D; O'Flaherty JT; Edwards IJ
Neoplasia; 2009 Oct; 11(10):1042-53. PubMed ID: 19794963
[TBL] [Abstract][Full Text] [Related]
19. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
[TBL] [Abstract][Full Text] [Related]
20. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
Lai KP; Huang CK; Chang YJ; Chung CY; Yamashita S; Li L; Lee SO; Yeh S; Chang C
Am J Pathol; 2013 Feb; 182(2):460-73. PubMed ID: 23219429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
